Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer

被引:0
|
作者
Jos Jonkers
Ralph Meuwissen
Hanneke van der Gulden
Hans Peterse
Martin van der Valk
Anton Berns
机构
[1] Netherlands Cancer Institute,Division of Molecular Genetics and Centre of Biomedical Genetics
[2] Netherlands Cancer Institute,Department of Pathology
来源
Nature Genetics | 2001年 / 29卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Inheritance of one defective BRCA2 allele predisposes humans to breast cancer. To establish a mouse model for BRCA2-associated breast cancer, we generated mouse conditional mutants with BRCA2 and/or p53 inactivated in various epithelial tissues, including mammary-gland epithelium. Although no tumors arose in mice carrying conditional Brca2 alleles, mammary and skin tumors developed frequently in females carrying conditional Brca2 and Trp53 alleles. The presence of one wildtype Brca2 allele resulted in a markedly delayed tumor formation; loss of the wildtype Brca2 allele occurred in a subset of these tumors. Our results show that inactivation of BRCA2 and of p53 combine to mediate mammary tumorigenesis, and indicate that disruption of the p53 pathway is pivotal in BRCA2-associated breast cancer.
引用
收藏
页码:418 / 425
页数:7
相关论文
共 50 条
  • [1] Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer
    Jonkers, J
    Meuwissen, R
    van der Gulden, H
    Peterse, H
    van der Valk, M
    Berns, A
    NATURE GENETICS, 2001, 29 (04) : 418 - 425
  • [2] BRCA2 and p53 work together in breast cancer
    Nasir, J
    LANCET ONCOLOGY, 2002, 3 (02): : 69 - 69
  • [3] A mouse model of sporadic breast tumor with a conditional P53 mutation
    Zhang, Y.
    Xiong, S.
    Pant, V.
    El-Naggar, A.
    Lozano, G.
    CANCER RESEARCH, 2016, 76
  • [4] Advancements in targeting tumor suppressor genes (p53 and BRCA 1/2) in breast cancer therapy
    Nainwal, Nidhi
    Murti, Yogesh
    Yadav, Savita
    Rawat, Pramod
    Dhiman, Sonia
    Kumar, Bhupinder
    MOLECULAR DIVERSITY, 2024,
  • [5] Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer
    Shimada, Shu
    Mimata, Ayako
    Sekine, Masaki
    Mogushi, Kaoru
    Akiyama, Yoshimitsu
    Fukamachi, Hiroshi
    Jonkers, Jos
    Tanaka, Hiroshi
    Eishi, Yoshinobu
    Yuasa, Yasuhito
    GUT, 2012, 61 (03) : 344 - 353
  • [6] Breast cancer in young women: prevalence of LOH at p53, BRCA1 and BRCA2
    SM Johnson
    JA Shaw
    RA Walker
    Breast Cancer Research, 2 (Suppl 1)
  • [7] Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos
    Ludwig, T
    Chapman, DL
    Papaioannou, VE
    Efstratiadis, A
    GENES & DEVELOPMENT, 1997, 11 (10) : 1226 - 1241
  • [8] BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability
    Gretarsdottir, S
    Thorlacius, S
    Valgardsdottir, R
    Gudlaugsdottir, S
    Sigurdsson, S
    Steinarsdottir, M
    Jonasson, JG
    Anamthawat-Jonsson, K
    Eyfjörd, JE
    CANCER RESEARCH, 1998, 58 (05) : 859 - 862
  • [9] Structure and mechanism of action of the BRCA2 breast cancer tumor suppressor
    Shahid, Taha
    Soroka, Joanna
    Kong, Eric H.
    Malivert, Laurent
    McIlwraith, Michael J.
    Pape, Tillmann
    West, Stephen C.
    Zhang, Xiaodong
    NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2014, 21 (11) : 962 - 968
  • [10] Structure and mechanism of action of the BRCA2 breast cancer tumor suppressor
    Taha Shahid
    Joanna Soroka
    Eric H Kong
    Laurent Malivert
    Michael J McIlwraith
    Tillmann Pape
    Stephen C West
    Xiaodong Zhang
    Nature Structural & Molecular Biology, 2014, 21 : 962 - 968